Hrt Financial LP Kinnate Biopharma Inc. Transaction History

Hrt Financial LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$2.33 - $6.84 $24,243 - $71,170	10,405 New	10,405 $31,000
Q2 2022 Aug 12, 2022	SELL	$7.43 - $13.0 $681,353 - $1.19 Million	-91,703 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$7.73 - $17.99 $708,864 - $1.65 Million	91,703 New	91,703 $1.03 Million
Q3 2021 Nov 15, 2021	SELL	$17.81 - $24.87 $359,993 - $502,697	-20,213 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$22.19 - $31.55 $448,526 - $637,720	20,213 New	20,213 $470,000
Q1 2021 May 17, 2021	SELL	$26.99 - $40.0 $151,602 - $224,680	-5,617 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$36.35 - $45.25 $204,177 - $254,169	5,617 New	5,617 $223,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.